28th Jun 2021 14:52
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing (Note 1) | J.P. Morgan Securities LLC |
Company dealt in | Xeris Pharmaceuticals, Inc. |
Class of relevant security to which the dealings being disclosed relate (Note 2) | $0.001 common stock |
Date of dealing | 25 June 2021 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
| Long | Short | ||||
| Number |
| (%) | Number |
| (%) |
(1) Relevant securities | 3,358,325 5.06 | 745,699 1.12 | ||||
(2) Derivatives (other than options) | 263,078 0.40 |
| ||||
(3) Options and agreements to purchase/sell |
|
| ||||
Total | 3,621,403 5.46 | 745,699 1.12 | ||||
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale |
Number of relevant securities |
Price per unit (USD)
(Note 5) |
Purchase(Loan Return)
Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases
Sales Sales Sales Sales Sales Sales Sales Sales Sales | 22,000
100 105 35,100 31,837 100 68 3,315 603 1,960 200 409 32,395 166 1,071 62,906 2,394 300 11,391 2,464 100 1,453 6,963 100 100 201 100
54,893 1,071 62,906 344 100 300 245 201 101 | N/A
4.9600 USD 4.8600 USD 4.8103 USD 4.8100 USD 4.7950 USD 4.7900 USD 4.7751 USD 4.7747 USD 4.7478 USD 4.7450 USD 4.7402 USD 4.7273 USD 4.7200 USD 4.7065 USD 4.6958 USD 4.6704 USD 4.6544 USD 4.6464 USD 4.6321 USD 4.6304 USD 4.6300 USD 4.6022 USD 4.5100 USD 4.4600 USD 4.4533 USD 4.3900 USD
4.8100 USD 4.7065 USD 4.6958 USD 4.6400 USD 4.6000 USD 4.5600 USD 4.5500 USD 4.4533 USD 4.3800 USD |
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD | Nature of transaction (Note 6) | Number of relevant securities (Note 7) | Price per unit (USD) (Note 5) |
Equity Swap | Decrease Long | 62,906 1,071 | 4.6959 USD 4.7065 USD |
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option | Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 5) |
|
|
|
|
|
|
|
(ii) Exercising
Product name, e.g. call option | Number of securities | Exercise price per unit (Note 5) |
|
|
|
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
|
|
|
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the
voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition
or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
None
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure | 28 June 2021 |
Contact name | Alwyn Basch |
Telephone number | 0207 742 7407 |
If a connected EFM, name of offeree/offeror with which connected | N/A |
If a connected EFM, state nature of connection (Note 10) | N/A |
Related Shares:
Xeris Biopharma